V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240012762 | 240008972 | 1.85 | 94.5 | Adjuvant (A) | 2015-12-08 | 2015-12-16 | Ofatumumab Loading | 2 | N | 240030743 | CISPLATIN + GEMCITABINE |
| 240012763 | 240008974 | null | 57.8 | null | 2016-03-04 | 2016-03-08 | CAV | N | N | 240030881 | VEDEX |
| 240012764 | 240008975 | 1.82 | 93.7 | Palliative (P) | 2016-09-12 | 2016-09-12 | RCD TRIAL | 02 | N | 240031006 | CYTARABINE HD + METHOTREXATE HD |
| 240012765 | 240012794 | 1.61 | null | Curative (C) | null | 2018-02-13 | CHOEP | N | null | 240031120 | IMATINIB |
| 240012766 | 240008977 | 1.73 | 92.6 | Curative (C) | 2014-02-12 | 2014-02-18 | BCNUTT | 02 | null | 240031448 | TOPOTECAN |
| 240012767 | 240008978 | 1.65 | 86 | Curative (C) | 2018-07-25 | 2018-07-28 | FEC 60 or 75 | 02 | N | 240031751 | IVAC |
| 240012768 | 240008978 | 1.53 | 62 | Curative (C) | 2015-11-18 | 2015-12-09 | Irinotecan + Modified De Gramont | N | N | 240031751 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240012769 | 240008979 | 1.59 | 68.9 | Palliative (P) | 2015-03-22 | 2015-04-18 | CARBOPLATIN + RT | null | null | 240031958 | ESHAP R |
| 240012770 | 240008981 | 0 | 80.4 | Curative (C) | 2016-12-22 | 2017-01-14 | PEMBROLIZUMAB | null | N | 240032004 | DTPACE |
| 240012771 | 240008982 | null | 76.8 | null | 2016-09-22 | 2016-09-23 | TOPOTECAN | N | N | 240032168 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240012772 | 240012797 | 1.63 | 122 | null | 2016-09-20 | 2016-09-26 | CLADRIBINE | 01 | N | 240032220 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240012773 | 240012798 | 1.54 | null | Curative (C) | 2015-04-24 | 2015-04-26 | Capecitabine + Oxaliplatin 21day | N | null | 240032233 | CETUXIMAB |
| 240012774 | 240014585 | 1.73 | 58.7 | Curative (C) | 2016-03-08 | 2016-03-08 | CISPLATIN + GEMCITABINE + RITUXIMAB | 01 | N | 240032239 | AML18 TRIAL |
| 240012775 | 240015937 | 1.54 | 40.2 | Palliative (P) | 2015-01-04 | 2015-01-16 | CHOEP | 02 | N | 240032251 | CARBOPLATIN + TOPOTECAN |
| 240012776 | 240008984 | 1.65 | 79 | Curative (C) | 2016-10-25 | 2016-10-25 | IVE-R | N | null | 240032654 | AML16 TRIAL |
| 240012777 | 240008985 | 1.66 | 71 | Curative (C) | 2015-08-03 | 2015-10-30 | R-PMitCEBOM | Y | N | 240032654 | LIPOSOMAL CYTARABINE |
| 240012778 | 240012800 | 1.65 | null | Curative (C) | 2013-11-27 | 2013-11-27 | REMODLB TRIAL | 1 | N | 240032911 | CARBOPLATIN + VINORELBINE |
| 240012779 | 240008987 | 1.7 | 115 | Curative (C) | 2017-08-11 | 2017-08-11 | AML 19 TRIAL | Y | N | 240033354 | VINORELBINE |
| 240012780 | 240008989 | null | 73.4 | Disease modification (D) | 2018-06-11 | 2018-06-11 | IDELALISIB + RITUXIMAB | 02 | N | 240033472 | ECX |
| 240012781 | 240008989 | 1.63 | 41.9 | Curative (C) | 2015-05-28 | 2015-05-30 | VINCRISTINE | 02 | N | 240033472 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 240012782 | 240008989 | 1.79 | null | Curative (C) | 2014-04-26 | 2014-05-19 | ETOPOSIDE | N | null | 240033472 | CYTARABINE IT + METHOTREXATE |
| 240012783 | 240008990 | null | 83.1 | Curative (C) | 2013-03-14 | 2014-06-01 | Cytarabine HD + Methotrexate HD | 02 | N | 240033903 | BENDAMUSTINE + OFATUMUMAB |
| 240012784 | 240008992 | 1.45 | 58.5 | Neo-adjuvant (N) | 2014-11-28 | 2015-01-20 | Carboplatin + Docetaxel | 01 | N | 240034000 | IRINOTECAN + MDG |
| 240012785 | 240008992 | 0 | 60 | Curative (C) | 2013-11-04 | 2014-01-15 | AML17 TRIAL | 2 | N | 240034000 | GEMCITABINE + VINORELBINE |
| 240012786 | 240008995 | 1.82 | 70 | Curative (C) | 2016-03-04 | 2016-03-10 | R-GDP | 2 | N | 240034221 | IVE + METHOTREXATE |
| 240012787 | 240008995 | 1.79 | 55.4 | Disease modification (D) | 2015-03-22 | 2015-03-23 | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + VINCRISTINE | null | N | 240034221 | CHOEP |
| 240012788 | 240008996 | 0 | 90 | Curative (C) | 2015-02-10 | 2015-02-10 | ICE-R | N | N | 240034290 | CLOFARABINE + CYTARABINE |
| 240012789 | 240012805 | 1.65 | 69.7 | Palliative (P) | 2015-12-20 | 2015-12-28 | Trabectedin | 02 | N | 240034474 | CISPLATIN + FLUOROURACIL + RT |
| 240012790 | 240008997 | 1.66 | 77.5 | Curative (C) | 2016-02-16 | 2016-02-20 | AML 18 TRIAL | N | N | 240034474 | CISPLATIN + FLUOROURACIL |
| 240012791 | 240008997 | 1.66 | 89.8 | Disease modification (D) | 2017-09-02 | 2017-11-21 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 240034474 | VINCRISTINE |
| 240012792 | 240008997 | 1.76 | 80.7 | Palliative (P) | 2015-11-07 | 2016-02-02 | AML17 TRIAL | N | N | 240034474 | R CODOX-M/ R IVAC |
| 240012793 | 240008997 | null | null | Curative (C) | 2018-03-21 | 2018-04-13 | Carboplatin + Topotecan | null | null | 240034474 | LENALIDOMIDE + RITUXIMAB |
| 240012794 | 240008999 | null | null | null | 2018-11-22 | 2019-01-07 | G-CVP | null | N | 240035558 | VEDEX |
| 240012795 | 240014591 | 1.69 | 68.2 | Curative (C) | 2017-08-26 | 2017-09-06 | Ofatumumab Monthly | 2 | N | 240035615 | DHAP - R |
| 240012796 | 240009001 | 1.61 | 47.5 | Curative (C) | 2016-05-10 | 2016-05-20 | DHAP - R | 2 | N | 240004804 | PILOT TRIAL |
| 240012797 | 240009003 | 1.72 | 60.1 | null | 2018-12-21 | 2018-12-22 | VINCRISTINE | Y | N | 240004804 | TOPOTECAN |
| 240012798 | 240009004 | 1.62 | null | null | 2017-07-29 | 2017-08-21 | DOXORUBICIN | null | N | 240006774 | RITUXIMAB + TEMOZOLOMIDE |
| 240012799 | 240009006 | null | 91.5 | Adjuvant (A) | 2016-02-29 | 2016-02-29 | R-CHOEP | N | N | 240006808 | BORTEZOMIB + THALIDOMIDE |
| 240012800 | 240009006 | null | 70.8 | Palliative (P) | 2018-07-17 | 2018-10-31 | CYTARABINE + METHOTREXATE HD | N | null | 240006808 | IVAC |
| 240012801 | 240009008 | 1.65 | null | Palliative (P) | 2014-12-05 | 2014-12-29 | Carboplatin + Topotecan | N | N | 240007272 | DHAP - R |
| 240012802 | 240009010 | 1.76 | 67.3 | Palliative (P) | 2017-02-01 | 2017-02-01 | CISPLATIN + GEMCITABINE | 2 | Y | 240011413 | CYTARABINE HIGH DOSE |
| 240012803 | 240009011 | 1.71 | 0 | Curative (C) | 2017-05-04 | 2017-05-04 | VEDex | 2 | null | 240012412 | PEMBROLIZUMAB |
| 240012804 | 240012816 | 0 | 61.2 | Disease modification (D) | null | 2016-09-25 | CYTARABINE + METHOTREXATE | N | N | 240012412 | OFATUMUMAB |
| 240012805 | 240009013 | 1.77 | 100 | Curative (C) | 2018-05-12 | 2018-06-05 | IDARAM | N | N | 240014616 | DHAP - R |
| 240012806 | 240009014 | 1.75 | 82.5 | Disease modification (D) | 2014-11-27 | 2014-11-27 | NHL 2003 Gp B CYM 1 & 2 | N | N | 240015382 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 240012807 | 240009015 | null | null | Curative (C) | 2017-12-07 | 2018-01-05 | VINCRISTINE | N | N | 240015867 | NILOTINIB |
| 240012808 | 240009016 | 1.76 | 50 | Curative (C) | 2013-09-24 | 2013-10-02 | Cytarabine intrathecal | N | N | 240016293 | ESHAP |
| 240012809 | 240009017 | 1.77 | null | Curative (C) | null | 2016-06-14 | VEDex | N | null | 240019083 | CODOX M |
| 240012810 | 240009018 | 1.69 | 115 | null | 2016-01-07 | 2016-01-12 | AML17 TRIAL | N | N | 240019083 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240012811 | 240009019 | 0 | 80 | Curative (C) | 2017-01-22 | 2017-02-09 | DA-EPOCH-R | N | N | 240019885 | GEMCITABINE + VINORELBINE |